January 29, 2015
Press Release
Mitsubishi Tanabe Pharma Corporation-Increasing Production Capacity to Meet Growing Asian Pharmaceutical Markets Completion of New Manufacturing FacilityTianjin Tanabe Seiyaku Co., Ltd. and P.T. Tanabe Indonesia
Osaka, Japan, January 29, 2015 - Mitsubishi Tanabe Pharma Corporation (President &Representative Director, CEO: Masayuki Mitsuka; hereinafter, "the Company") announced today thatthe construction of new facilities have been completed at the plants of Tianjin Tanabe Seiyaku Co.,
Ltd. (Head Office: Tianjin, China) and P.T. Tanabe Indonesia (Head Office: Special Capital Region ofJakarta, Indonesia), overseas consolidated subsidiaries of the Company.

Under the Company’s Medium-Term Management Plan 11-15, New Value Creation, establishingfoundations for expanded overseas operations has been set as a major business strategy inpromoting the Company’s business activities. In Asia, including China, the Company strives not only
to introduce products that have been approved in Japan, the US and Europe as rapidly as possible,
but also to introduce products proactively in line with the needs and characteristics of each market.
Because Chinese and Indonesian pharmaceutical markets are expected to grow further withincreasing GDP, the Company has moved ahead with the construction of new buildings to increase
production capacity to address this growing demand and to meet China's new GMP and Indonesia's
PIC/S-GMP, newly-implemented GMP standards.

The Company has already started business activities in China, with Tianjin Tanabe Seiyaku Co., Ltd.
dedicated to manufacture and sales of pharmaceuticals, Mitsubishi Pharma Research &Development (Beijing) Co., Ltd. (Head Office: Beijing) dedicated to development of pharmaceuticals,and Guangdong Tanabe Pharmaceutical Co., Ltd. (Head Office: Guangzhou) dedicated to sales ofpharmaceuticals. With the start of operation at the new facilities that will boost production capacity to300 million tablets per year, the Company’s business operations are expected to expand still further.
-Continued1

Since its establishment in 1970, P.T. Tanabe Indonesia has been manufacturing pharmaceuticalproducts for supply to Indonesia and its neighboring countries. Commencement of operation at thenew facility will boost the plant's production capability by 1.75 times from the current level for a major
product, Herbesser, an antihypertensive drug, and other solid preparations. The new facility willserve as a manufacturing base for Southeast Asia.

The Company will utilize these new facilities as a foundation for expanded operations in growing
Asian markets and ensure a stable supply of high-quality pharmaceuticals. Furthermore, theCompany will fulfill its responsibilities as a "global research-driven pharmaceutical company that istrusted by communities" by striving to contribute to the health of people around the world.

For the outline of each subsidiary and the new building, refer to the separate attachment.

<<For further information, contact>>
Corporate Communications Department
Phone: +81-6-6205-5211

2

ReferenceTianjin Tanabe Seiyaku
Corporate name: Tianjin Tanabe Seiyaku Co., Ltd.
Representatives: Chairman Zheng jie
President Norihiko Okada
Foundation: October 1993
Paid-in capital: 16.23 million U.S. dollars
Equity holders: 75.35% by Mitsubishi Tanabe Pharma and 24.65% by Tianjin Lisheng PharmaceuticalCo., Ltd.
Business activities: Production and sales of pharmaceuticals
Annual sales: about ¥3.6 billion (for the year ended in December 2013)
Main products: Herbesser, Tanatril, Cerekinon, Gastrom, Talion
Production capacity: about 200 million tablets (as of the end of December 2014)
No. of employees: 521 (as of the end of December 2014)

Outline of new manufacturing facility
Location: No. 16 MIP Third Road, Micro-Electronics Industrial Park, Tianjin Economic-Technological
Development Area, Tianjin, China
Start of construction: August 2013
Completion: January 2015
2
Scale of new facility: 2-story building(construction area: about 5,800 m ,2
total floor space: about 7,200m )Total construction cost: about ¥1.9 billion (planned)
Designing and construction: Dalian Kaiser Construction Co., Ltd.

External appearance:3P.T. Tanabe Indonesia
Corporate name: P.T. Tanabe Indonesia
Representatives: President Kazuyuki Kashiba
Foundation: July 1970
Paid-in capital: 2.5 million U.S. dollars
Equity holders: 99.6% by Mitsubishi Tanabe PharmaBusiness activities: Production and sales of pharmaceuticals
Annual sales: about ¥2.5 billion (for the year ended in March 2014)
Main products: Herbesser, Tanatril, Maintate, Livalo
Production capacity: about 100 million tablets (as of the end of December 2014)
No. of employees: 469 (as of the end of December 2014)

Outline of a production facility
Location: Jl. Rumah Sakit 104, Ujungberung, Bandung 40612, Indonesia
Start of construction: September 2013
Completion: January 2015
Scale of new facility: 3-story building (construction area: about 1,200 m2,
total floor space: about 2,800m2)
Total construction cost: about ¥800 million
Designing and construction:

P.T. SMCC UTAMA INDONESIA(Sumitomo Mitsui Construction Co., Ltd.)

External appearance:4